The effect of helium on the immune system ex vivo

The effect of helium on the immune system ex vivo - HeLIX

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33293

Enrollment

Registered

2009-02-05

Start date

2009-04-01

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immuun modulerend effect Immunomodulating effects

Interventions

Volunteers will be studied during two separate days, in which they will breath heliox or room air for 30 min using a special, sealed mask.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Non-smoking, healthy, male volunteers, aged 18-45 years, informed consent

Exclusion criteria

Exclusion criteria: Smoking, current or in the past six months Alcohol or drug abuse Allergic reaction to medication in past medical history Chronic medication use that could influence the immune system Presence of any condition that could influence the immune system

Design outcomes

Primary

Measure	Time frame
The main parameters of this study will be proinflammatory cytokines determined after ex vivo stimulation of whole blood. The cytokines are: IL-1beta, IL-6, TNF-alfa, the chemokine IL-8, T-cell products IL-2 and INF-gamma and a neutrophil degranulation product: elastase.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)